Search Our Science Our pipeline Innovation that advances cancer care Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs. The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. Program ALL ALL Brentuximab vedotin (ADCETRIS®) Learn More Phase 1 Phase 2 Phase 3 R/R Diffuse large B-Cell lymphoma SGN35-31: + lenalidomide, rituximab 1L Hodgkin lymphoma (HL) SGN35-27: + nivolumab, doxorubicin and dacarbazine 1L HL or PTCL (unfit for combination chemotherapy) SGN35-15: Monotherapy R/R HL and PTCL SGN35-28: Retreatment R/R HL (pediatrics) CheckMate 744: + nivolumab 1L PTCL (< 10% CD30 expression) + cyclophosphamide, doxorubicin and prednisone R/R Metastatic solid tumors pembrolizumab post PD-1 Enfortumab vedotin-ejfv (PADCEV®) Learn More Phase 1 Phase 2 Phase 3 1L Locally advanced or metastatic urothelial cancer EV-302: + pembrolizumab, +/- chemotherapy Locally advanced or metastatic urothelial cancer* EV-301: Post PD(L)-1 and post platinum chemotherapy 1L Muscle invasive bladder cancer EV-303/KEYNOTE-905: + pembrolizumab, cisplatin ineligible Muscle invasive bladder cancer EV-304/KEYNOTE-B15: + pembrolizumab, cisplatin eligible Locally advanced or metastatic urothelial cancer*† EV-201: Cohort 2 post PD(L)-1, platinum naïve and cisplatin ineligible 1L/2L Locally advanced or metastatic urothelial or muscle-invasive cancer EV-103: +/- pembrolizumab Locally advanced or metastatic solid tumors EV-202: Monotherapy 1L Muscle invasive bladder cancer EV-103: +/- pembrolizumab Tucatinib (TUKYSA®) Learn More Phase 1 Phase 2 Phase 3 HER2CLIMB-02 –  Metastatic HER2+ breast cancer HER2CLIMB-02: + T-DM1 High risk HER2+ breast cancer CompassHER2 RD** HER2+ metastatic breast cancer + trastuzumab deruxtecan R/R HER2+ metastatic colorectal cancer† MOUNTAINEER: + trastuzumab HER2+ gastroesophageal cancer 2L MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy Metastatic solid tumors HER2 alterations + trastuzumab, +/- fulvestrant 1L HER2+ gastric cancer + trastuzumab, oxaliplatin Tisotumab vedotin Learn More Phase 1 Phase 2 Phase 3 2L/3L Metastatic/recurrent cervical cancer innovaTV 301: Monotherapy 2L/3L Recurrent or metastatic cervical cancer†‡ innovaTV 204: Monotherapy 1L/2L Recurrent or metastatic cervical cancer innovaTV 205: + other anti-cancer agents Locally advanced solid tumors innovaTV 206 (Japan only) R/R Metastatic solid tumors innovaTV 207: Monotherapy Platinum-resistant ovarian cancer innovaTV 208: Monotherapy Ladiratuzumab vedotin Learn More Phase 1 Phase 2 Phase 3 1L Metastatic triple-negative breast cancer + pembrolizumab R/R Metastatic solid tumors Monotherapy R/R Metastatic breast cancer (HR+/HER2-) Monotherapy SEA-BCMA Phase 1 Phase 2 Phase 3 R/R Multiple myeloma +/- dexamethasone SEA-CD40 Phase 1 Phase 2 Phase 3 R/R Pancreatic cancer +/- pembrolizumab, gemcitabine, nab-paclitaxel SGN-CD228A Phase 1 Phase 2 Phase 3 R/R Solid tumors Monotherapy SEA-CD70 Phase 1 Phase 2 Phase 3 R/R MDS/AML Monotherapy SEA-TGT Phase 1 Phase 2 Phase 3 R/R Solid tumors and lymphoma +/- pembrolizumab SGN-B6A Phase 1 Phase 2 Phase 3 R/R Solid tumors Monotherapy SGN-STNV Phase 1 Phase 2 Phase 3 R/R Solid tumors Monotherapy SGN-CD30C Phase 1 Phase 2 Phase 3 Lymphoma 1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma. *Enrollment Complete **The trial is being conducted by the Alliance for Clinical Trials in Oncology †Pivotal Trial ‡Top-line Data Reported Download our Pipeline Request additional information Request additional information about an investigational therapy or report an adverse event. Contact Medical Information Patients and Caregivers Diseases We Study Real Stories Clinical Trials Support and Resources Healthcare Professionals Medical Information Clinical Data Requests Investigator-Sponsored Research Medical Education Grants Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms > Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept